- Home
- IAF vs CGTX Comparison
IAF vs CGTX Comparison
Compare IAF & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IAF | CGTX |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | IAF | CGTX |
|---|---|---|
| Price | $13.96 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 90.4K | ★ 909.6K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | ★ 11.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.60 | $0.22 |
| 52 Week High | $4.59 | $3.83 |
Technical Indicators
Market Signals| Indicator | IAF | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 80.13 | 41.59 |
| Support Level | $13.11 | $1.37 |
| Resistance Level | $13.31 | $1.49 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 99.99 | 9.62 |
Price Performance
Historical ComparisonAbout IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.